>
Akero Therapeutics Inc logo

AKRO - Akero Therapeutics Inc Share Price

$27.34 -0.3  -0.9%

Last Trade - 16/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £687.4m
Enterprise Value £493.3m
Revenue £n/a
Position in Universe 2875th / 6850
Bullish
Bearish
Unlock AKRO Revenue
Momentum
Relative Strength (%)
1m -21.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AkeroTherapeutics Inc revenues was not reported. Net lossincreased 81% to $79.2M. Higher net loss reflects Researchand development - Balancing increase of 73% to $63.3M(expense), General and administrative - Balancing increaseof 44% to $10.5M (expense), Stock-based Compensation in SGAincrease from $1.3M to $4.4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AKRO Revenue Unlock AKRO Revenue

Net Income

AKRO Net Income Unlock AKRO Revenue

Normalised EPS

AKRO Normalised EPS Unlock AKRO Revenue

PE Ratio Range

AKRO PE Ratio Range Unlock AKRO Revenue

Dividend Yield Range

AKRO Dividend Yield Range Unlock AKRO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
AKRO EPS Forecasts Unlock AKRO Revenue
Profile Summary

Akero Therapeutics Inc. is a cardio-metabolic non-alcoholic steatohepatitis (NASH) company. The Company is focused on developing medicines designed to restore metabolic balance and improve the overall health of patients with NASH. Its lead product candidate is Efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). Efruxifermin is designed to address the processes underlying NASH pathogenesis, with the potential to restore healthy fat metabolism in the liver, reduce hepatocyte stress, mitigate inflammation and resolve fibrosis. It is developing Efruxifermin in a separate cohort evaluating treatment of patients with compensated cirrhosis (F4).

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated January 24, 2017
Public Since June 20, 2019
No. of Shareholders: 5
No. of Employees: 21
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 34,770,319
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AKRO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AKRO
Upcoming Events for AKRO
Frequently Asked Questions for Akero Therapeutics Inc
What is the Akero Therapeutics Inc share price?

As of 16/04/21, shares in Akero Therapeutics Inc are trading at $27.34, giving the company a market capitalisation of £687.4m. This share price information is delayed by 15 minutes.

How has the Akero Therapeutics Inc share price performed this year?

Shares in Akero Therapeutics Inc are currently trading at $27.34 and the price has moved by 29.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Akero Therapeutics Inc price has moved by -10.94% over the past year.

What are the analyst and broker recommendations for Akero Therapeutics Inc?

There are no analysts currently covering Akero Therapeutics Inc.

When will Akero Therapeutics Inc next release its financial results?

Akero Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Akero Therapeutics Inc dividend yield?

Akero Therapeutics Inc does not currently pay a dividend.

Does Akero Therapeutics Inc pay a dividend?

Akero Therapeutics Inc does not currently pay a dividend.

When does Akero Therapeutics Inc next pay dividends?

Akero Therapeutics Inc does not currently pay a dividend.

How do I buy Akero Therapeutics Inc shares?

To buy shares in Akero Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Akero Therapeutics Inc?

Shares in Akero Therapeutics Inc are currently trading at $27.34, giving the company a market capitalisation of £687.4m.

Where are Akero Therapeutics Inc shares listed? Where are Akero Therapeutics Inc shares listed?

Here are the trading details for Akero Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AKRO
What kind of share is Akero Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Akero Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Akero Therapeutics Inc share price forecast 2021?

Shares in Akero Therapeutics Inc are currently priced at $27.34. At that level they are trading at 0.122% discount to the analyst consensus target price of 0.00.

Analysts covering Akero Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -4.111 for the next financial year.

How can I tell whether the Akero Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akero Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -20.76%. At the current price of $27.34, shares in Akero Therapeutics Inc are trading at -11.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Akero Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Akero Therapeutics Inc.

Who are the key directors of Akero Therapeutics Inc?

Akero Therapeutics Inc's management team is headed by:

Andrew Cheng - PRE
Jonathan Young - CFD
William White - CFO
Timothy Rolph - CFD
Kitty Yale - OTH
Kevin Bitterman - NID
Seth Harrison - NID
Jane Henderson - NID
Mark Iwicki - NEC
Tomas Heyman - IND
Who are the major shareholders of Akero Therapeutics Inc?

Here are the top five shareholders of Akero Therapeutics Inc based on the size of their shareholding:

Apple Tree Partners Venture Capital
Percentage owned: 16.77% (5.83m shares)
Janus Henderson Investors Investment Advisor/Hedge Fund
Percentage owned: 10.05% (3.49m shares)
VenBio Partners LLC Private Equity
Percentage owned: 7.03% (2.44m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.68% (2.32m shares)
Atlas Venture Venture Capital
Percentage owned: 6.35% (2.21m shares)
Similar to AKRO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.